Coulter Partners places experienced R&D leader and biotech entrepreneur as CEO of Nuage Therapeutics
London, May 14, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Dr. Stuart Hughes as Chief Executive Officer at Nuage Therapeutics S.L. (“Nuage”).
Nuage is a biotech company focused on creating transformational precision therapies by targeting established oncogenic transcription factors. The Company has developed a set of tools that enables the reconstitution of intrinsically-disordered proteins (IDPs) in a secondary-structured form that renders them amenable to small molecule drug discovery thereby unlocking a wide range of previously intractable but important drug targets with a robust human biological basis for therapeutic intervention.
Dr. Stuart Hughes has broad R&D leadership experience in a range of settings having worked in drug discovery across multiple therapeutic areas. He joins Nuage from Pathios Therapeutics, an immuno-oncology company where he served as CEO and where he built the company from an initial seed investment to a clinical-stage organization. During this period, he led the completion of a €25 million Series B first close, that included the addition of Bristol Myers Squibb as a strategic investor, to support ongoing Phase 1 studies. Previously, he was a Senior Director at the global biotech, Vertex Pharmaceuticals and before then, he was a Principal Research Scientist in CNS disorders at Eli Lilly. He has a MSc in Electrical & Electronic Engineering and a PhD in Neuroscience from Cardiff University.
Commenting on his appointment, Dr. Hughes, new CEO of Nuage, said:
Nuage possesses a highly differentiated suite of technologies that enables the capture of ‘disordered’ proteins in a form that is amenable to small molecule screening and profiling. I believe Nuage represents a game-changing advance in drug discovery and precision medicine, especially where targets have previously been considered undruggable. Allied to a highly skilled team and the support of top-tier investors, Nuage is ideally positioned for growth and success. I look forward to getting started.
Reflecting on the collaboration with Coulter Partners, Vanessa Malier, Chair of the Board of Directors of Nuage Therapeutics added:
Coulter Partners has been an invaluable partner in this crucial appointment for Nuage Therapeutics. Their team demonstrated exceptional dedication and a truly collaborative spirit, working closely with me to realize the ambitions of both Sofinnova and Asabys to build impactful companies with strong leadership. We particularly appreciated their flexibility and adaptability throughout the process, ultimately enabling us to secure an outstanding CEO who aligns perfectly with our vision for Nuage's future.
